A study by Gonzalo Martınez et al., published in the Journal of the American Heart Association indicates that colchicine may also be useful for the treatment of heart attacks by reducing cardiac inflammation and the local pro-inflammatory cytokine production.
Colchicine is an alkaloid with potent anti-inflammatory effects, which is often used for the treatment of gout, and other inflammatory conditions such as pericarditis.
The international research team from Australia, Chile, France and the UK found that colchicine given to patients with acute coronary syndrome, the day before a cardiac catheterization, significantly reduced the intracardiac release of interleukin (IL)-1β, IL-18, and IL-6. These cytokines are major players in atherosclerotic inflammation, and contribute to the atherosclerotic plaque development, progression and destabilization.
This study may suggest a new treatment strategy that could reduce the incidence of new coronary events, which are common after acute coronary syndrome.